Source: Eur Respir J, 52 (6) 1802111; 10.1183/13993003.02111-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Marlies S. Wijsenbeek, Mirjam Kool, Vincent Cottin. Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end. Eur Respir J, 52 (6) 1802111; 10.1183/13993003.02111-2018

Member's Comments

No comment yet.

Related content which might interest you: Targeted treatment of idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2016; 47:1321-1323 Year: 2016 Epithelial pIgR: A new player in idiopathic pulmonary fibrosis? Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases Year: 2018 Role of interleukin-10 in idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 179-180 Year: 2004 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 IGFBP-2 a new interesting target in IPF Source: International Congress 2016 – ILD pathogenesis Year: 2016 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Mechanism of bronchoalveolar duct junction (BADJ) remodeling in idiopathic pulmonary fibrosis (IPF) as base for new pathogenetic therapy Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)? Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018